Format
Sort by

Send to

Choose Destination

Search results

Items: 2

1.

Clinical impact of the M184V mutation on switching to didanosine or maintaining lamivudine treatment in nucleoside reverse-transcriptase inhibitor-experienced patients.

Winters MA, Bosch RJ, Albrecht MA, Katzenstein DA; AIDS Clinical Trials Group 364 Study Team..

J Infect Dis. 2003 Aug 15;188(4):537-40. Epub 2003 Jul 24.

PMID:
12898440
2.

Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.

Albrecht MA, Bosch RJ, Hammer SM, Liou SH, Kessler H, Para MF, Eron J, Valdez H, Dehlinger M, Katzenstein DA; AIDS Clinical Trials Group 364 Study Team..

N Engl J Med. 2001 Aug 9;345(6):398-407.

Supplemental Content

Loading ...
Support Center